

David Jayne

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2377403/publications.pdf>

Version: 2024-02-01

176
papers

10,910
citations

57631

44
h-index

32761

100
g-index

182
all docs

182
docs citations

182
times ranked

9045
citing authors

#	ARTICLE	IF	CITATIONS
1	2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 736-745.	0.5	1,265
2	A Randomized Trial of Maintenance Therapy for Vasculitis Associated with Antineutrophil Cytoplasmic Autoantibodies. <i>New England Journal of Medicine</i> , 2003, 349, 36-44.	13.9	1,239
3	2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1151-1159.	0.5	759
4	Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. <i>New England Journal of Medicine</i> , 2017, 376, 1921-1932.	13.9	682
5	Eosinophilic granulomatosis with polyangiitis (Churgâ€“Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. <i>European Journal of Internal Medicine</i> , 2015, 26, 545-553.	1.0	371
6	Revised 2017 international consensus on testing of ANCA in granulomatosis with polyangiitis and microscopic polyangiitis. <i>Nature Reviews Rheumatology</i> , 2017, 13, 683-692.	3.5	302
7	A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 554-561.	0.5	268
8	The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. <i>Rheumatology</i> , 2018, 57, e1-e45.	0.9	247
9	BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis. <i>Rheumatology</i> , 2014, 53, 2306-2309.	0.9	246
10	Kainate receptors: Pharmacology, function and therapeutic potential. <i>Neuropharmacology</i> , 2009, 56, 90-113.	2.0	242
11	The glutamate story. <i>British Journal of Pharmacology</i> , 2006, 147, S100-S108.	2.7	223
12	2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1799-1807.	0.5	220
13	Damage in the anca-associated vasculitides: long-term data from the European Vasculitis Study group (EUVAS) therapeutic trials. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 177-184.	0.5	214
14	The NMDA receptor as a target for cognitive enhancement. <i>Neuropharmacology</i> , 2013, 64, 13-26.	2.0	206
15	Long-term potentiation and the role of N -methyl- d -aspartate receptors. <i>Brain Research</i> , 2015, 1621, 5-16.	1.1	199
16	Autologous stem cell transplantation for systemic lupus erythematosus. <i>Lupus</i> , 2004, 13, 168-176.	0.8	169
17	Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 399-405.	0.5	165
18	Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1662-1668.	0.5	159

#	ARTICLE	IF	CITATIONS
19	2015 Recommendations for the Management of Polymyalgia Rheumatica: A European League Against Rheumatism/American College of Rheumatology Collaborative Initiative. <i>Arthritis and Rheumatology</i> , 2015, 67, 2569-2580.	2.9	146
20	Revisiting the systemic vasculitis in eosinophilic granulomatosis with polyangiitis (Churg-Strauss). <i>Autoimmunity Reviews</i> , 2017, 16, 1-9.	2.5	140
21	Respiratory manifestations of eosinophilic granulomatosis with polyangiitis (Churg-Strauss). <i>European Respiratory Journal</i> , 2016, 48, 1429-1441.	3.1	102
22	Synthesis of Willardiine and 6-Azawillardiine Analogs: Pharmacological Characterization on Cloned Homomeric Human AMPA and Kainate Receptor Subtypes. <i>Journal of Medicinal Chemistry</i> , 1997, 40, 3645-3650.	2.9	99
23	ANCA serotype and histopathological classification for the prediction of renal outcome in ANCA-associated glomerulonephritis. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1764-1769.	0.4	99
24	Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 63-73.	0.4	96
25	Pharmacological antagonism of the actions of group II and III mGluR agonists in the lateral perforant path of rat hippocampal slices. <i>British Journal of Pharmacology</i> , 1996, 117, 1457-1462.	2.7	93
26	Characterisation of UBP296: a novel, potent and selective kainate receptor antagonist. <i>Neuropharmacology</i> , 2004, 47, 46-64.	2.0	92
27	Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 496-506.	0.5	87
28	Predictors of renal and patient outcomes in anti-GBM disease: clinicopathologic analysis of a two-centre cohort. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 814-821.	0.4	85
29	Long-Term Followup of a Multicenter Cohort of 101 Patients With Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss). <i>Arthritis Care and Research</i> , 2016, 68, 374-387.	1.5	82
30	Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 2170-2177.	1.5	82
31	A Novel Family of Negative and Positive Allosteric Modulators of NMDA Receptors. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2010, 335, 614-621.	1.3	80
32	2020 international consensus on ANCA testing beyond systemic vasculitis. <i>Autoimmunity Reviews</i> , 2020, 19, 102618.	2.5	79
33	Pharmacological modulation of NMDA receptor activity and the advent of negative and positive allosteric modulators. <i>Neurochemistry International</i> , 2012, 61, 581-592.	1.9	77
34	The diagnosis of vasculitis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2009, 23, 445-453.	1.4	76
35	The effects of (RS)-cyclopropylphosphonophenylglycine ((RS)-CPPG), a potent and selective metabotropic glutamate receptor antagonist. <i>British Journal of Pharmacology</i> , 1996, 119, 851-854.	2.7	75
36	Allosteric Block of KCa2 Channels by Apamin. <i>Journal of Biological Chemistry</i> , 2010, 285, 27067-27077.	1.6	71

#	ARTICLE	IF	CITATIONS
37	ANCA-Associated Vasculitis: An Update. <i>Journal of Clinical Medicine</i> , 2021, 10, 1446.	1.0	70
38	Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis. <i>RMD Open</i> , 2019, 5, e000905.	1.8	66
39	B cell therapy in ANCA-associated vasculitis: current and emerging treatment options. <i>Nature Reviews Rheumatology</i> , 2018, 14, 580-591.	3.5	61
40	Guidelines on the use of irradiated blood components. <i>British Journal of Haematology</i> , 2020, 191, 704-724.	1.2	61
41	Clinical Features and Radiological Findings in Large Vessel Vasculitis: Are Takayasu Arteritis and Giant Cell Arteritis 2 Different Diseases or a Single Entity?. <i>Journal of Rheumatology</i> , 2015, 42, 300-308.	1.0	54
42	Characteristics and Outcomes of Granulomatosis With Polyangiitis (Wegener) and Microscopic Polyangiitis Requiring Renal Replacement Therapy: Results From the European Renal Associationâ€“European Dialysis and Transplant Association Registry. <i>American Journal of Kidney Diseases</i> , 2015, 66, 613-620.	2.1	52
43	End-stage renal disease in ANCA-associated vasculitis. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, gfw046.	0.4	51
44	Multicriteria decision analysis process to develop new classification criteria for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 634-640.	0.5	51
45	Review article: Progress of treatment in ANCAâ€“associated vasculitis. <i>Nephrology</i> , 2009, 14, 42-48.	0.7	46
46	A genome-wide association study suggests the HLA Class II region as the major susceptibility locus for IgA vasculitis. <i>Scientific Reports</i> , 2017, 7, 5088.	1.6	44
47	Positive and Negative Allosteric Modulators of <i>N</i> -Methyl-D-aspartate (NMDA) Receptors: Structureâ€“Activity Relationships and Mechanisms of Action. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 3-23.	2.9	44
48	The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults: Executive Summary. <i>Rheumatology</i> , 2018, 57, 14-18.	0.9	43
49	Prevalence and Responsiveness to Treatment of Lung Abnormalities on Chest Computed Tomography in Patients With Microscopic Polyangiitis: A Multicenter, Longitudinal, Retrospective Study of One Hundred Fifty Consecutive Hospitalâ€“Based Japanese Patients. <i>Arthritis and Rheumatology</i> , 2016, 68, 713-723.	2.9	42
50	Negative anti-neutrophil cytoplasm antibody at switch to maintenance therapy is associated with a reduced risk of relapse. <i>Arthritis Research and Therapy</i> , 2017, 19, 129.	1.6	42
51	Comparisons of Guidelines and Recommendations on Managing Antineutrophil Cytoplasmic Antibodyâ€“Associated Vasculitis. <i>Kidney International Reports</i> , 2018, 3, 1039-1049.	0.4	41
52	A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibodyâ€“associated vasculitis. <i>Rheumatology</i> , 2019, 58, 260-268.	0.9	40
53	Challenges in the management of microscopic polyangiitis: past, present and future. <i>Current Opinion in Rheumatology</i> , 2008, 20, 3-9.	2.0	39
54	Role of Rituximab Therapy in Glomerulonephritis. <i>Journal of the American Society of Nephrology: JASN</i> , 2010, 21, 14-17.	3.0	39

#	ARTICLE	IF	CITATIONS
55	Targeting B Cells and Plasma Cells in Glomerular Diseases: Translational Perspectives. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 741-758.	3.0	39
56	Coumarin-3-carboxylic acid derivatives as potentiators and inhibitors of recombinant and native N-methyl-d-aspartate receptors. <i>Neurochemistry International</i> , 2012, 61, 593-600.	1.9	37
57	European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 775-781.	0.5	37
58	Current Attitudes to the Therapy of Vasculitis. <i>Kidney and Blood Pressure Research</i> , 2003, 26, 231-239.	0.9	34
59	Structure-activity relationships for allosteric NMDA receptor inhibitors based on 2-naphthoic acid. <i>Neuropharmacology</i> , 2012, 62, 1730-1736.	2.0	33
60	Multiple roles of GluN2B-containing NMDA receptors in synaptic plasticity in juvenile hippocampus. <i>Neuropharmacology</i> , 2017, 112, 76-83.	2.0	33
61	Subclassifying ANCA-associated vasculitis: a unifying view of disease spectrum. <i>Rheumatology</i> , 2019, 58, 1707-1709.	0.9	32
62	Elicitation of Expert Prior Opinion: Application to the MYPAN Trial in Childhood Polyarteritis Nodosa. <i>PLoS ONE</i> , 2015, 10, e0120981.	1.1	32
63	(S)-homomquisqualate: a potent agonist at the glutamate metabotropic receptor. <i>British Journal of Pharmacology</i> , 1992, 106, 509-510.	2.7	30
64	Incidence and predictors of severe infections in ANCA-associated vasculitis: a population-based cohort study. <i>Rheumatology</i> , 2021, 60, 2745-2754.	0.9	30
65	Long-term Outcome of Airway Stenosis in Granulomatosis With Polyangiitis (Wegener) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 34	1.2	29
66	Lupus nephritis and B-cell targeting therapy. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 951-962.	1.3	29
67	Renal involvement in eosinophilic granulomatosis with polyangiitis (EGPA): a multicentric retrospective study of 63 biopsy-proven cases. <i>Rheumatology</i> , 2021, 60, 359-365.	0.9	27
68	Outcome assessment in Takayasu arteritis. <i>Rheumatology</i> , 2016, 55, 1159-1171.	0.9	26
69	Some distorted thoughts about ketamine as a psychedelic and a novel hypothesis based on NMDA receptor-mediated synaptic plasticity. <i>Neuropharmacology</i> , 2018, 142, 30-40.	2.0	26
70	Clinical associations with venous thromboembolism in anti-neutrophil cytoplasm antibody-associated vasculitides. <i>Rheumatology</i> , 2017, 56, kew465.	0.9	24
71	ANCA associated vasculitis: The journey to complement-targeted therapies. <i>Molecular Immunology</i> , 2019, 112, 394-398.	1.0	23
72	How to induce remission in primary systemic vasculitis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2005, 19, 293-305.	1.4	21

#	ARTICLE	IF	CITATIONS
73	The European Vasculitis Society 2016 Meeting Report. <i>Kidney International Reports</i> , 2017, 2, 1018-1031.	0.4	21
74	Complement inhibition in ANCA vasculitis. <i>Nephrologie Et Therapeutique</i> , 2019, 15, 409-412.	0.2	21
75	Increasing incidence and improved survival in ANCA-associated vasculitis—a Danish nationwide study. <i>Nephrology Dialysis Transplantation</i> , 2021, 37, 63-71.	0.4	21
76	Proteinase-3 and myeloperoxidase serotype in relation to demographic factors and geographic distribution in anti-neutrophil cytoplasmic antibody-associated glomerulonephritis. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 301-308.	0.4	20
77	Genetic Variants in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Bayesian Approach and Systematic Review. <i>Journal of Clinical Medicine</i> , 2019, 8, 266.	1.0	19
78	Structural basis of subtype-selective competitive antagonism for GluN2C/2D-containing NMDA receptors. <i>Nature Communications</i> , 2020, 11, 423.	5.8	19
79	Venous thromboembolism in ANCA-associated vasculitis: a population-based cohort study. <i>Rheumatology</i> , 2021, 60, 4616-4623.	0.9	19
80	A retrospective study comparing the phenotype and outcomes of patients with polyarteritis nodosa between UK and Turkish cohorts. <i>Rheumatology International</i> , 2018, 38, 1833-1840.	1.5	18
81	Twenty-five years of European Union collaboration in ANCA-associated vasculitis research. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, i1-i7.	0.4	17
82	Putative Receptors Underpinning l-Lactate Signalling in Locus Coeruleus. <i>Neuroglia (Basel)</i> Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 382 Td	0.3	17
83	Use and reporting of outcome measures in randomized trials for anti-neutrophil cytoplasmic antibody-associated vasculitis: a systematic literature review. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1314-1325.	1.6	17
84	Vasculitis—when can biopsy be avoided?. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, 1454-1456.	0.4	15
85	Mechanism and properties of positive allosteric modulation of N -methyl- d -aspartate receptors by 6-alkyl 2-naphthoic acid derivatives. <i>Neuropharmacology</i> , 2017, 125, 64-79.	2.0	15
86	Sustained remission in lupus nephritis: still a hard road ahead. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 2011-2018.	0.4	14
87	New perspectives in eosinophilic granulomatosis with polyangiitis (EGPA): report of the first meeting of the European EGPA Study Group. <i>Internal and Emergency Medicine</i> , 2019, 14, 1193-1197.	1.0	13
88	The NMDA receptor intracellular C-terminal domains reciprocally interact with allosteric modulators. <i>Biochemical Pharmacology</i> , 2019, 159, 140-153.	2.0	13
89	Heart disease in eosinophilic granulomatosis with polyangiitis (EGPA) patients: a screening approach proposal. <i>Rheumatology</i> , 2021, 60, 4538-4547.	0.9	13
90	Vascular imaging of patients with refractory Takayasu arteritis treated with tocilizumab: <i>post hoc</i> analysis of a randomized controlled trial. <i>Rheumatology</i> , 2022, 61, 2360-2368.	0.9	13

#	ARTICLE	IF	CITATIONS
91	Treatment of ANCA-associated systemic small-vessel vasculitis. <i>Apmis</i> , 2009, 117, 3-9.	0.9	12
92	Comment on: The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults: reply. <i>Rheumatology</i> , 2018, 57, 1502-1503.	0.9	12
93	Alemtuzumab for refractory primary systemic vasculitis—a randomised controlled dose ranging clinical trial of efficacy and safety (ALEVIATE). <i>Arthritis Research and Therapy</i> , 2022, 24, 81.	1.6	12
94	Long-term outcomes of patients with Takayasu arteritis and renal artery involvement: a cohort study. <i>Rheumatology Advances in Practice</i> , 2018, 2, rky026.	0.3	11
95	“In my beginning is my end” usefulness of repeat kidney biopsies in lupus nephritis. <i>Kidney International</i> , 2020, 97, 27-29.	2.6	11
96	Development of a score for assessment of radiologic damage in large-vessel vasculitis (Combined) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50</i>	0.4	11
97	Investigation of the structural requirements for N-methyl-D-aspartate receptor positive and negative allosteric modulators based on 2-naphthoic acid. <i>European Journal of Medicinal Chemistry</i> , 2019, 164, 471-498.	2.6	10
98	Multiple roles of GluN2D-containing NMDA receptors in short-term potentiation and long-term potentiation in mouse hippocampal slices. <i>Neuropharmacology</i> , 2021, 201, 108833.	2.0	10
99	Phenylglycine derivatives as antagonists of group III metabotropic glutamate receptors expressed on neonatal rat primary afferent terminals. <i>British Journal of Pharmacology</i> , 2003, 139, 1523-1531.	2.7	9
100	Synthesis of a Series of Novel 3,9-Disubstituted Phenanthrenes as Analogues of Known N-Methyl-d-aspartate Receptor Allosteric Modulators. <i>Synthesis</i> , 2015, 47, 1593-1610.	1.2	9
101	<p>Systemic vasculitis and patient-reported outcomes: how the assessment of patient preferences and perspectives could improve outcomes</p>. <i>Patient Related Outcome Measures</i> , 2019, Volume 10, 37-42.	0.7	9
102	Quality indicators for systemic lupus erythematosus based on the 2019 EULAR recommendations: development and initial validation in a cohort of 220 patients. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1175-1182.	0.5	9
103	The Startle Disease Mutation E103K Impairs Activation of Human Homomeric $\hat{\pm}1$ Glycine Receptors by Disrupting an Intersubunit Salt Bridge across the Agonist Binding Site. <i>Journal of Biological Chemistry</i> , 2017, 292, 5031-5042.	1.6	8
104	Integrated safety profile of atacicept: an analysis of pooled data from the atacicept clinical trial programme. <i>Rheumatology Advances in Practice</i> , 2019, 3, rkz021.	0.3	8
105	The relapsing polychondritis damage index (RPDAM): Development of a disease-specific damage score for relapsing polychondritis. <i>Joint Bone Spine</i> , 2019, 86, 363-368.	0.8	8
106	Treating vasculitis with conventional immunosuppressive agents. <i>Cleveland Clinic Journal of Medicine</i> , 2012, 79, S46-S49.	0.6	8
107	Clinical management and treatment of vasculitis. <i>Seminars in Immunopathology</i> , 2001, 23, 267-286.	4.0	7
108	Actions of LY341495 on metabotropic glutamate receptor-mediated responses in the neonatal rat spinal cord. <i>British Journal of Pharmacology</i> , 2003, 139, 147-155.	2.7	7

#	ARTICLE	IF	CITATIONS
109	Stem cell transplantation in systemic lupus erythematosus. <i>Best Practice and Research in Clinical Haematology</i> , 2004, 17, 291-304.	0.7	7
110	New-generation therapy for ANCA-associated vasculitis. <i>Clinical and Experimental Nephrology</i> , 2013, 17, 694-696.	0.7	7
111	Clinical Trials in Vasculitis. <i>Current Treatment Options in Rheumatology</i> , 2016, 2, 161-177.	0.6	7
112	A single-channel mechanism for pharmacological potentiation of GluN1/GluN2A NMDA receptors. <i>Scientific Reports</i> , 2017, 7, 6933.	1.6	7
113	322.â€ŒA RANDOMISED, DOUBLE-BLIND, CONTROLLED, MECHANISTIC STUDY OF RITUXIMAB AND BELIMUMAB COMBINATION THERAPY IN PR3 ANCA-ASSOCIATED VASCULITIS (COMBIVAS): STUDY PROTOCOL. <i>Rheumatology</i> , 2019, 58, .	0.9	7
114	Assembly and Trafficking of Homomeric and Heteromeric Kainate Receptors with Impaired Ligand Binding Sites. <i>Neurochemical Research</i> , 2019, 44, 585-599.	1.6	7
115	Baricitinib set to join the Covid-19 therapeutic arsenal?. <i>Rheumatology</i> , 2021, 60, 1585-1587.	0.9	7
116	A case of <i>de novo</i> diagnosis antiâ€œneutrophil cytoplasmic antibodyâ€œnegative pauciâ€œimmune necrotising glomerulonephritis in pregnancy. <i>Internal Medicine Journal</i> , 2017, 47, 600-601.	0.5	6
117	Urinary MCP-1 and TWEAK as non-invasive markers of disease activity and treatment response in patients with lupus nephritis in South Africa. <i>International Urology and Nephrology</i> , 2021, 53, 1865-1873.	0.6	6
118	Synthesis and pharmacological characterisation of arctigenin analogues as antagonists of AMPA and kainate receptors. <i>Organic and Biomolecular Chemistry</i> , 2021, 19, 9154-9162.	1.5	6
119	Infection is associated with increased risk of MPO- but not PR3-ANCA-associated vasculitis. <i>Rheumatology</i> , 2022, 61, 4817-4826.	0.9	6
120	Synthesis and biological evaluation of phospholane and dihydrophosphole analogues of the glutamate receptor agonist AP4Electronic supplementary information (ESI) available: mode of epoxide ring-opening and experimental data for 2 and 3. See http://www.rsc.org/suppdata/p1/b2/b204891d/ . <i>Journal of the Chemical Society, Perkin Transactions 1</i> , 2002, , 1625-1627.	1.3	5
121	L27. Antibodies versus phenotypes: A clinician's view. <i>Presse Medicale</i> , 2013, 42, 579-582.	0.8	5
122	An interchangeable role for kainate and metabotropic glutamate receptors in the induction of rat hippocampal mossy fiber longâ€œterm potentiation in vivo. <i>Hippocampus</i> , 2015, 25, 1407-1417.	0.9	5
123	S2. Rituximab for ANCA-associated vasculitis: The UK experience. <i>Presse Medicale</i> , 2013, 42, 532-534.	0.8	4
124	Comment on: A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibodyâ€œassociated vasculitis: reply. <i>Rheumatology</i> , 2019, 58, 738-739.	0.9	4
125	Iatrogenic antibody deficiency from B-cell targeted therapies in autoimmune rheumatic diseases. <i>Lupus Science and Medicine</i> , 2019, 6, e000337.	1.1	4
126	Developing a composite outcome tool to measure response to treatment in ANCA-associated vasculitis: A mixed methods study from OMERACT 2020. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1134-1138.	1.6	4

#	ARTICLE	IF	CITATIONS
127	Saving the kidneys in the lupus patient: Beyond immunosuppression, the need to collaborate across multiple disciplines. <i>European Journal of Internal Medicine</i> , 2022, 99, 19-21.	1.0	4
128	361.â€ŒTHE EFFECT OF REDUCED-DOSE ORAL GLUCOCORTICOIDS DURING INDUCTION OF REMISSION INDUCTION IN SEVERE ANCA-ASSOCIATED VASCULITIS. <i>Rheumatology</i> , 2019, 58, .	0.9	3
129	The clinical features and pathology of vasculitis associated with anti-myeloperoxidase autoantibodies. <i>Japanese Journal of Infectious Diseases</i> , 2004, 57, S16-7.	0.5	3
130	The Excitatory Amino Acid System. , 0, , 67-84.		2
131	The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales. <i>Rheumatology</i> , 2017, 56, 1041-1043.	0.9	2
132	Response to: â€ŒPrevention of infections in patients with antineutrophil cytoplasm antibody-associated vasculitis: potential role of hydroxychloroquineâ€™ by Novikov<i>et al</i>. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e20-e20.	0.5	2
133	FC 039RENAL OUTCOME AFTER RITUXIMAB IN ADULT-ONSET IGA VASCULITIS AND CRESCENTIC IGA NEPHROPATHY: A MULTICENTRE STUDY. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.4	2
134	An international Delphi exercise to identify items of importance for measuring response to treatment in ANCA-associated vasculitis. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 55, 152021.	1.6	2
135	Preface. <i>Best Practice and Research in Clinical Rheumatology</i> , 2009, 23, 305-307.	1.4	1
136	Biologic Treatment in Glomerular Disease. <i>Nephron Clinical Practice</i> , 2015, 128, 203-204.	2.3	1
137	Progressive multifocal leucoencephalopathy with BehÃŒetâ€™s disease: an insight into pathophysiology. <i>Rheumatology</i> , 2017, 56, kew404.	0.9	1
138	Preface. <i>Best Practice and Research in Clinical Rheumatology</i> , 2018, 32, 1-2.	1.4	1
139	296.â€ŒPLASMA EXCHANGE AS A NOVEL TREATMENT FOR IGA VASCULITIS WITH NEPHRITIS. <i>Rheumatology</i> , 2019, 58, .	0.9	1
140	030.â€ŒTOLERABILITY AND CELL YIELD FROM NASAL BIOPSIES OBTAINED IN THE OUTPATIENT SETTING. <i>Rheumatology</i> , 2019, 58, .	0.9	1
141	FC058: Long-Term Renal Survival of Anca-Associated Vasculitis Patients Included in the Euvas Randomized Clinical Trials. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.4	1
142	FC060: Malignancies in Patients With Anca-Associated Vasculitis Treated within the Euvas Trials. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.4	1
143	MO040ASSOCIATION OF A TNFSF13B (BAFF) REGULATORY REGION SINGLE NUCLEOTIDE POLYMORPHISMS WITH RESPONSE TO RITUXIMAB IN ANCA-ASSOCIATED VASCULITIS. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, i45-i46.	0.4	0
144	TO039RISK OF VENOUS THROMBOEMBOLIC EVENTS IN ANCA ASSOCIATED VASCULITIS. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, i77-i78.	0.4	0

#	ARTICLE	IF	CITATIONS
145	SaO020RITUXIMAB AS MAINTENANCE THERAPY FOR SYSTEMIC LUPUS ERYTHEMATOSUS. Nephrology Dialysis Transplantation, 2018, 33, i323-i323.	0.4	0
146	297.â€fRENAL INVOLVEMENT IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS. Rheumatology, 2019, 58, .	0.9	0
147	158.â€fINCIDENCE AND PREDICTORS OF SEVERE INFECTIONS IN ANCA-ASSOCIATED VASCULITIS IN A POPULATION-BASED COHORT â€“ PRELIMINARY RESULTS. Rheumatology, 2019, 58, .	0.9	0
148	159.â€fINFECTIONS ARE ASSOCIATED WITH INCREASED RISK OF MPO- BUT NOT PR3-ANCA-ASSOCIATED VASCULITIS - A POPULATION-BASED CASE-CONTROL STUDY FROM SOUTHERN SWEDEN. Rheumatology, 2019, 58, .	0.9	0
149	176.â€fTHE COMPOSITION OF THE HUMAN NASAL MICROBIOME IN GRANULOMATOSIS WITH POLYANGIITIS: A PILOT STUDY. Rheumatology, 2019, 58, .	0.9	0
150	239.â€fRISK FACTORS FOR THE DEVELOPMENT OF CHRONIC KIDNEY DISEASE IN ADULTS WITH IGA VASCULITIS. Rheumatology, 2019, 58, .	0.9	0
151	247.â€fCHARACTERISTICS, OUTCOMES AND PROGNOSTIC FACTORS OF PATIENTS WITH ACUTE MANIFESTATION OF SMALL VESSEL VASCULITIS ADMITTED TO INTENSIVE CARE: AN 18-YEAR SINGLE-CENTRE EXPERIENCE. Rheumatology, 2019, 58, .	0.9	0
152	255.â€fRENAL INVOLVEMENT IN EGPA: A MULTICENTRE RETROSPECTIVE STUDY OF 63 CASES. Rheumatology, 2019, 58, .	0.9	0
153	261.â€fASSESSMENT OF RADIOLOGIC DAMAGE IN LARGE-VESSEL VASCULITIS (COMBINED ARTERITIS DAMAGE) T1ETQq1 10.78431	0.9	0
154	354.â€fEFFICACY OF EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS TREATMENTS ACCORDING TO THE TYPE OF MANIFESTATIONS BASED ON ANALYSIS OF 636 PATIENTS. Rheumatology, 2019, 58, .	0.9	0
155	356.â€fRITUXIMAB ASSOCIATED HYPOGAMMAGLOBULINAEMIA IN AUTOIMMUNE DISEASE: LONG TERM OUTCOMES. Rheumatology, 2019, 58, .	0.9	0
156	153.â€fTHE 10-YEAR LONG-TERM FOLLOW-UP OF PATIENTS WITH ANCA-ASSOCIATED VASCULITIS INCLUDED IN EUROPEAN VASCULITIS SOCIETY RANDOMISED CLINICAL TRIALS SINCE 1995: A SURVIVAL ANALYSIS. Rheumatology, 2019, 58, .	0.9	0
157	330.â€fTREATMENT RESPONSE CRITERIA FOR ANCA-ASSOCIATED VASCULITIS: RESULTS OF A SCOPING REVIEW. Rheumatology, 2019, 58, .	0.9	0
158	242â€fBaseline characteristics of patients with lupus nephritis requiring rituximab therapy: results from the British Isles Lupus Assessment Group Biologics Register (BILAG-BR). Rheumatology, 2019, 58, .	0.9	0
159	360.â€fTHE EFFECT OF PLASMA EXCHANGE ON END-STAGE RENAL DISEASE AND DEATH IN PATIENTS WITH SEVERE ANCA-ASSOCIATED VASCULITIS. Rheumatology, 2019, 58, .	0.9	0
160	117.â€fPREDICTION OF LONG-TERM EVOLUTIONARY PROFILES IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (CHURGâ€“ STRAUSS) BASED ON BASELINE AND FOLLOW-UP CHARACTERISTICS. Rheumatology, 2019, 58, .	0.9	0
161	210â€f...Integrated safety profile of atacicept from all clinical studies to date. , 2019, , ,		0
162	Response to: â€“Mycophenolate mofetil: a step forward in the induction treatment of ANCA-associated vasculitis? Comment on the article by Jones<i>et alâ€™™</i>by Vandergheynst<i>et al</i>. Annals of the Rheumatic Diseases, 2020, 79, e101-e101.	0.5	0

#	ARTICLE	IF	CITATIONS
163	A case of type B insulin resistance presenting at a district general hospital. <i>Practical Diabetes</i> , 2020, 37, 93-95.	0.1	0
164	Performance of the EULAR/ACR 2019 classification criteria for systemic lupus erythematosus in men, ethnicities, and early disease. , 2020, , .		0
165	P0373MEPOLIZUMAB THERAPY FOR EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA) - ONE YEAR FOLLOW-UP STUDY USING ANTI-IL5 AS A STEROID SPARING THERAPEUTIC APPROACH. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.4	0
166	Is There a Role for LAMP-2 Autoantibodies in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitis?. <i>Journal of Rheumatology</i> , 2020, 47, 636-638.	1.0	0
167	Comment on: Subclassifying ANCA-associated vasculitis: a unifying view of disease spectrum: reply. <i>Rheumatology</i> , 2020, 59, 1187-1187.	0.9	0
168	PR3-ANCA associated retinal vasculitis and atrial myxoma. <i>Rheumatology</i> , 2021, 60, e5-e6.	0.9	0
169	FC 033LONG-TERM FOLLOW-UP OF PATIENTS WITH ANCA-ASSOCIATED VASCULITIS INCLUDED IN EUROPEAN VASCULITIS SOCIETY RANDOMIZED CLINICAL TRIALS SINCE 1995: A SURVIVAL ANALYSIS. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.4	0
170	FC 032THE EFFECT OF AVACOPAN, A COMPLEMENT C5A RECEPTOR INHIBITOR, ON KIDNEY FUNCTION IN PATIENTS WITH ANCA-ASSOCIATED VASCULITIS WITH RENAL DISEASE. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.4	0
171	MO245OUTCOME OF DIFFERENT INDUCTION REGIMENS IN ANCA-ASSOCIATED GLOMERULONEPHRITIS ACCORDING TO THE HISTOPATHOLOGICAL CHARACTERISTICS: THE REASSESS STUDY*. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.4	0
172	FC 049A RANDOMISED DOSE RANGING, PLACEBO-CONTROLLED, PHASE II STUDY ASSESSING THE EFFICACY AND SAFETY OF BI 655064, AN ANTAGONISTIC ANTI-CD40 ANTIBODY, IN PATIENTS WITH LUPUS NEPHRITIS. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.4	0
173	MO271PROGNOSIS OF NON-PR3 ANCA-ASSOCIATED VASCULITIDES WITH RENAL INVOLVEMENT. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.4	0
174	Pharmacological characterization of a novel negative allosteric modulator of NMDA receptors, UBP792. <i>Neuropharmacology</i> , 2021, 201, 108818.	2.0	0
175	Gating Effects of a Novel Allosteric Modulator at GluN1/GluN2A NMDA Receptors. <i>FASEB Journal</i> , 2015, 29, 933.3.	0.2	0
176	FC057: Incidence of Infections in the Avacopan Group Versus Prednisone Group in Anca-Associated Vasculitis, Results from the Phase 3 Advocate Study. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.4	0